SCHEMBL2670567

SCHEMBL2670567

CC(C)C[C@H](N)C(=O)N(CCCCNC(=O)OC(C)(C)C)C(=O)OCc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.49
RECQL P46063 1/20 0.49
KMT2A Q03164 1/20 0.49
MAPT P10636 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
POLB P06746 2/20 0.44
MAPK1 P28482 1/20 0.44
SYK P43405 1/20 0.44
IDO1 P14902 1/20 0.43
SLC1A3 P43003 1/20 0.41
SLC1A1 P43005 1/20 0.41
DPP8 Q6V1X1 1/20 0.41
DPP7 Q9UHL4 1/20 0.41
FOLH1 Q04609 1/20 0.40
GPR55 Q9Y2T6 1/20 0.40
KLK7 P49862 1/20 0.40
KLK5 Q9Y337 1/20 0.40
CAPN1 P07384 1/20 0.40
CAPN2 P17655 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13289727 0.83 MAPT (0.47) MEN1RECQLKMT2AMAPTL3MBTL1
SCHEMBL9713794 0.79 MAPT (0.49) MAPTL3MBTL1POLBMAPK1SYK
SCHEMBL1690942 0.79 MAPT (0.50) MEN1RECQLKMT2AMAPTL3MBTL1
SCHEMBL15355986 0.77 CCR6 (0.54) MEN1RECQLKMT2AMAPTL3MBTL1
SCHEMBL19732512 0.77 CCR6 (0.59) MAPTL3MBTL1POLBMAPK1SYK
SCHEMBL5490556 0.77 MAPT (0.59) MEN1RECQLKMT2AMAPTL3MBTL1
SCHEMBL20168169 0.77 MAPT (0.59) MEN1RECQLKMT2AMAPTL3MBTL1
SCHEMBL7979181 0.77 MAPT (0.59) MEN1RECQLKMT2AMAPTL3MBTL1
SCHEMBL12527802 0.76 MAPT (0.47) MEN1RECQLKMT2AMAPTL3MBTL1
SCHEMBL2539145 0.76 MAPT (0.50) MEN1KMT2AMAPTL3MBTL1SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9169289-B2 Peptide derivatives for treatment, prevention or alleviation of a condition associated with bone loss or low bone density or to inhibit osteoclast differentiation and stimulation STRONGBONE AB (SE) 2015-10-27 US disclosed
US-20140243274-A1 NOVEL PEPTIDE DERIVATIVES FOR TREATMENT, PREVENTION OR ALLEVIATION OF A CONDITION ASSOCIATED WITH BONE LOSS OR LOW BONE DENSITY OR TO INHIBIT OSTEOCLAST DIFFERENTIATION AND STIMULATION STRONGBONE AB (SE) 2014-08-28 US disclosed
US-8748370-B2 Peptide derivatives for treatment, prevention or alleviation of a condition associated with bone loss or low bone density or to inhibit osteoclast differentiation and stimulation STRONGBONE AB (SE) 2014-06-10 US disclosed
US-20120108515-A1 NOVEL PEPTIDE DERIVATIVES FOR TREATMENT, PREVENTION OR ALLEVIATION OF A CONDITION ASSOCIATED WITH BONE LOSS OR LOW BONE DENSITY OR TO INHIBIT OSTEOCLAST DIFFERENTIATION AND STIMULATION NEOBIOTICS AB (SE) 2012-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108515-A1 NOVEL PEPTIDE DERIVATIVES FOR TREATMENT, PREVENTION OR ALLEVIATION OF A CONDITION ASSOCIATED WITH BONE LOSS OR LOW BONE DENSITY OR TO INHIBIT OSTEOCLAST DIFFERENTIATION AND STIMULATION BMP2, SOST, BMP1 MEN1 1543/4885RECQL 4437/4885KMT2A 3531/4885
US-20140243274-A1 NOVEL PEPTIDE DERIVATIVES FOR TREATMENT, PREVENTION OR ALLEVIATION OF A CONDITION ASSOCIATED WITH BONE LOSS OR LOW BONE DENSITY OR TO INHIBIT OSTEOCLAST DIFFERENTIATION AND STIMULATION BMP2, CALCRL, ARG1 MEN1 1629/4885RECQL 3295/4885KMT2A 3536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.